Comunicaciones en congresos

Real-world clinical experience of the Galician Lung Cancer Group: Afatinib in patients with EGFR positive mutation.

Comunicaciones en congresos /

ASCO Meeting Library Sara Agraso Busto, Vanesa Varela, Natalia Fernández Núñez, Jose-luis Firvida, Lucía Santomé, Francisco Javier Afonso, Cristina Azpitarte, Noemi De […]

Real-world clinical experience of the Galician Lung Cancer Group: Afatinib in patients with EGFR positive mutation. Leer más »

S. Agraso Busto et al.
J Clin Oncol 37, 2019 (suppl; abstr e20654)

Utility of the Lung Inmune Prognostic Index (LIPI) in prognostication and disease control prediction in advanced NSCLC patients treated with nivolumab.

Comunicaciones en congresos /

Juan Ruiz Bañobre, María C Arese Manrique, Rosario García Campelo, Rafaele Lopez, Francisco J. Afonso Afonso, Joaquín Casal Rubio, Sergio Vázquez Estévez,

Utility of the Lung Inmune Prognostic Index (LIPI) in prognostication and disease control prediction in advanced NSCLC patients treated with nivolumab. Leer más »

J. Ruiz Bañobre et al.
J. Clin Oncol 37, 2019 (suppl; abstr e20645)

Third and successive-lines of chemotherapy in NSCLC patientes without therapeutic targets: Experience of the Grupo Gallego de Cáncer de Pulmón.

Comunicaciones en congresos /

Francisco Javier Afonso Afonso, Natalia Fernández Núñez, Rocio Vilchez Simo, Jose-luis Fírvida, Noemi de Dios Alvarez, Begoña Campos Balea, Laura María De

Third and successive-lines of chemotherapy in NSCLC patientes without therapeutic targets: Experience of the Grupo Gallego de Cáncer de Pulmón. Leer más »

F. Javier Afonso Afonso et al.
J. Clin Oncol 37, 2019 (suppl; abstr e20579)

Efficacy and safety of Crizotinib in patient with ALK positive non small cell lung cancer (NSCLC): Real-world findings.

Comunicaciones en congresos /

Cristina Azpitarte Raposeiras, Noemi de Dios Alvarez, Jorge Garica, Maria Carmen Areses Manrique, Natalia Fernández Nñuñez, Francisco J. Afonso Afonso, Margarita Amenedo,

Efficacy and safety of Crizotinib in patient with ALK positive non small cell lung cancer (NSCLC): Real-world findings. Leer más »

C. Azpitarte Raposeiras et al.
J. Clin Oncol 37, 2019 (suppl; abstr e20636)

Concurrent Chemoradiation (CChRT) for locally advanced stage III Non-Small Cell Lung Cancer (NSCLC) with Cisplatin and Vinorelbine and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group.

Comunicaciones en congresos /

2017 ASCO Annual Meeting

Concurrent Chemoradiation (CChRT) for locally advanced stage III Non-Small Cell Lung Cancer (NSCLC) with Cisplatin and Vinorelbine and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group. Leer más »


Abstract